Dietary Supplement
Palmitoylethanolamide (PEA)
Palmitoylethanolamide (PEA) is a dietary supplement with 4 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DIETARY SUPPLEMENT
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
2(50%)
Results Posted
0%(0 trials)
Phase Distribution
Ph not_applicable
1
25%
Ph phase_2
3
75%
Phase Distribution
0
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
3(75.0%)
N/ANon-phased studies
1(25.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(3)
Completed(1)
Detailed Status
Recruiting2
Completed1
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 23 (75.0%)
N/A1 (25.0%)
Trials by Status
completed125%
not_yet_recruiting125%
recruiting250%
Recent Activity
2 active trials
Showing 4 of 4
recruitingphase_2
Sleep and Stress Study
NCT07315516
not_yet_recruitingnot_applicable
Palmitoylethanolamide vs Ibuprofen for Pain After ESWL
NCT07316660
recruitingphase_2
Long-Term PEA Safety Study
NCT06717867
completedphase_2
A Trial of the Fatty Acid Amide Hydrolase Inhibitor Palmitoylethanolamide in Bipolar Depression
NCT06229977
Clinical Trials (4)
Showing 4 of 4 trials
NCT07315516Phase 2
Sleep and Stress Study
NCT07316660Not Applicable
Palmitoylethanolamide vs Ibuprofen for Pain After ESWL
NCT06717867Phase 2
Long-Term PEA Safety Study
NCT06229977Phase 2
A Trial of the Fatty Acid Amide Hydrolase Inhibitor Palmitoylethanolamide in Bipolar Depression
All 4 trials loaded
Drug Details
- Intervention Type
- DIETARY SUPPLEMENT
- Total Trials
- 4